DexCom, Inc. (NASDAQ:DXCM) Given Consensus Recommendation of “Moderate Buy” by Analysts

DexCom, Inc. (NASDAQ:DXCM) has earned a consensus rating of “Moderate Buy” from the sixteen research firms that are currently covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $110.73.

A number of research firms have recently issued reports on DXCM. Baird R W cut DexCom from a “strong-buy” rating to a “hold” rating in a report on Friday, July 26th. Royal Bank of Canada cut their price objective on DexCom from $130.00 to $120.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Wells Fargo & Company cut their price objective on DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a report on Friday, July 26th. Barclays cut their price objective on DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a report on Monday, July 29th. Finally, Robert W. Baird upped their price objective on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, August 5th.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, EVP Michael Jon Brown sold 652 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the transaction, the executive vice president now owns 66,249 shares of the company’s stock, valued at approximately $4,607,617.95. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,824 shares of company stock valued at $126,390 in the last 90 days. Insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in DXCM. Sound Income Strategies LLC raised its position in shares of DexCom by 41.7% in the 1st quarter. Sound Income Strategies LLC now owns 340 shares of the medical device company’s stock worth $47,000 after acquiring an additional 100 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of DexCom by 11.4% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 25,322 shares of the medical device company’s stock worth $3,512,000 after acquiring an additional 2,591 shares in the last quarter. Capital Insight Partners LLC raised its position in shares of DexCom by 41.3% in the 1st quarter. Capital Insight Partners LLC now owns 3,600 shares of the medical device company’s stock worth $499,000 after acquiring an additional 1,052 shares in the last quarter. KRS Capital Management LLC increased its position in DexCom by 11.7% during the 1st quarter. KRS Capital Management LLC now owns 2,680 shares of the medical device company’s stock valued at $372,000 after buying an additional 280 shares in the last quarter. Finally, Hodges Capital Management Inc. bought a new position in DexCom during the 1st quarter valued at approximately $347,000. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

DexCom stock opened at $74.85 on Friday. DexCom has a 52 week low of $62.34 and a 52 week high of $142.00. The business has a 50-day simple moving average of $70.13 and a 200 day simple moving average of $98.71. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The stock has a market cap of $29.77 billion, a price-to-earnings ratio of 48.29, a PEG ratio of 2.16 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same period in the previous year, the business earned $0.34 earnings per share. The firm’s revenue was up 15.3% on a year-over-year basis. On average, research analysts forecast that DexCom will post 1.69 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.